Abstract library

507 results for "curative surgery".
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
Authors:
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
Authors:
#1931 Quality of Life, Anxiety and Depression in Patients with NEN after Surgery
Introduction: Less is known about quality of life and psychiatric disorders in surgical cohort of NEN patients (pts.).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Nehara Begum
Authors:
#1269 CEA Level, Radical Surgery and CD56 Expression Are Prognostic Factors for Patients with Locoregional Gastrin-independent GNET
Introduction: Gastrin-independent gastric neuroendocrine tumors (GNETs) are highly malignant. Radical resections and lymphadenectomy are considered to be the only possible curative treatment for these tumors. However, the prognosis of gastrin-independent GNETs is not well defined.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Yuan Li
Authors:
#1674 Meta-Analysis of Recurrence after Curative Surgery of Pancreatic Neuroendocrine Tumors.
Introduction: Follow-up after curative surgery for pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence, however reliable recurrence rates are difficult to deduct from literature. Without this knowledge, appropriate follow-up regimens and indications for adjuvant treatment remain unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Cansu Genc
Authors:
#1056 Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases
Introduction: The value of surgical resection in the management of pancreatic neuroendocrine tumor (PNET) with liver metastases (LM) is still debated.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Stefano Partelli
Authors:
#1878 Measurement in Blood of a Circulating NET mRNA Gene to Predict Surgical Efficacy
Introduction: Surgery is the only curative treatment for GEP-NETs, but identifying post-surgery residual disease is difficult and often delayed.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Professor Mark Kidd
Authors:
Keywords: NETest, surgery, biomarker, NET
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
Authors:
#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
Authors:
#1234 100 Cases of Pancreatic Resections for Pancreatic Neuroendocrine Tumors. The Royal Free Hospital Experience
Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare neoplasms of variable grade of malignancy. Surgery is the only curative treatment.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Domenico Tamburrino
Authors: